OPKO IP Holdings II, Inc.

Quick facts

Phase 3 pipeline

• CTAP101 Injection · Immunology / Rare Genetic Disorders
  CTAP101 is a recombinant human C1-esterase inhibitor (C1-INH) that regulates complement and contact system activation to prevent hereditary angioedema attacks.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• OPKO IP Holdings II, Inc. portfolio CI brief
• OPKO IP Holdings II, Inc. pipeline updates RSS